Symbols / RIGL
RIGL Chart
About
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. In addition, the company has product candidates in clinical development with partners BerGenBio ASA, Eli Lilly and Company, and Daiichi Sankyo. It has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of Olutasidenib in AML and other hematologic cancers with IDH1mutations, as well as with collaborative network for neuro-oncology clinical trials to evaluate Olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 622.41M |
| Enterprise Value | 550.14M | Income | 113.30M | Sales | 282.08M |
| Book/sh | 6.48 | Cash/sh | 7.56 | Dividend Yield | — |
| Payout | 0.00% | Employees | 162 | IPO | — |
| P/E | 5.54 | Forward P/E | 8.64 | PEG | — |
| P/S | 2.21 | P/B | 5.29 | P/C | — |
| EV/EBITDA | 4.53 | EV/Sales | 1.95 | Quick Ratio | 1.94 |
| Current Ratio | 2.28 | Debt/Eq | 51.77 | LT Debt/Eq | — |
| EPS (ttm) | 6.19 | EPS next Y | 3.97 | EPS Growth | 108.60% |
| Revenue Growth | 25.60% | Earnings | 2026-03-03 | ROA | 38.93% |
| ROE | 220.06% | ROIC | — | Gross Margin | 83.09% |
| Oper. Margin | 40.91% | Profit Margin | 40.17% | Shs Outstand | 18.15M |
| Shs Float | 17.86M | Short Float | 21.10% | Short Ratio | 7.71 |
| Short Interest | — | 52W High | 52.24 | 52W Low | 15.50 |
| Beta | 1.09 | Avg Volume | 455.46K | Volume | 65.11K |
| Target Price | $51.60 | Recom | None | Prev Close | $34.51 |
| Price | $34.29 | Change | -0.64% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$51.60
Mean price target
2. Current target
$34.29
Latest analyst target
3. DCF / Fair value
$61.29
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$34.29
Low
$38.00
High
$71.00
Mean
$51.60
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-05 | up | Jefferies | Hold → Buy | $42 |
| 2025-11-05 | main | Cantor Fitzgerald | Neutral → Neutral | $38 |
| 2025-10-08 | reit | HC Wainwright & Co. | Buy → Buy | $57 |
| 2025-08-06 | main | Cantor Fitzgerald | Neutral → Neutral | $32 |
| 2025-05-07 | main | Cantor Fitzgerald | Neutral → Neutral | $23 |
| 2025-03-06 | main | Citigroup | Buy → Buy | $55 |
| 2025-03-05 | main | B. Riley Securities | Neutral → Neutral | $24 |
| 2025-03-05 | reit | HC Wainwright & Co. | Buy → Buy | $57 |
| 2025-01-23 | reit | HC Wainwright & Co. | Buy → Buy | $57 |
| 2025-01-22 | reit | HC Wainwright & Co. | Buy → Buy | $57 |
| 2025-01-14 | reit | HC Wainwright & Co. | Buy → Buy | $57 |
| 2024-12-10 | main | Cantor Fitzgerald | Neutral → Neutral | $25 |
| 2024-12-10 | main | B. Riley Securities | Neutral → Neutral | $20 |
| 2024-12-10 | reit | HC Wainwright & Co. | Buy → Buy | $57 |
| 2024-12-06 | main | B. Riley Securities | Neutral → Neutral | $27 |
| 2024-11-14 | main | Piper Sandler | Neutral → Neutral | $23 |
| 2024-11-12 | main | Citigroup | Buy → Buy | $49 |
| 2024-10-25 | reit | HC Wainwright & Co. | Buy → Buy | $57 |
| 2024-08-09 | main | HC Wainwright & Co. | Buy → Buy | $57 |
| 2024-06-25 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
- Insider Sale: Director at $RIGL Sells 4,000 Shares - Quiver Quantitative ue, 24 Feb 2026 22
- Rigel Insider Move: High-Profile Director Makes a Notable Stock Sale - TipRanks Wed, 25 Feb 2026 04
- RIGL Stock Rises 59% in a Year: Time to Buy, Hold or Sell? - Zacks Investment Research Mon, 16 Feb 2026 13
- Rigel Pharmaceuticals (RIGL) Earnings Expected to Grow: Should You Buy? - Finviz ue, 24 Feb 2026 16
- Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire Fri, 09 Jan 2026 08
- FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside? - Yahoo Finance Wed, 28 Jan 2026 08
- Should Value Investors Buy Rigel Pharmaceuticals (RIGL) Stock? - Nasdaq Wed, 03 Dec 2025 08
- Rigel Pharmaceuticals: Continued Financial Performance, Catalysts In 2026 (RIGL) - Seeking Alpha Mon, 26 Jan 2026 08
- IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential? - Zacks Investment Research ue, 24 Feb 2026 13
- Rigel Pharmaceuticals Appoints Michael P. Miller to Board - The Globe and Mail Wed, 04 Feb 2026 08
- Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update - Finviz ue, 24 Feb 2026 13
- Rigel Pharmaceuticals (RIGL) is a Great Momentum Stock: Should You Buy? - Yahoo Finance Fri, 05 Dec 2025 08
- Should Value Investors Buy Rigel Pharmaceuticals (RIGL) Stock? - Nasdaq Mon, 29 Sep 2025 07
- Rigel Pharmaceuticals: Behind The Huge Rally (NASDAQ:RIGL) - Seeking Alpha ue, 25 Nov 2025 08
- RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential? - Yahoo Finance hu, 25 Sep 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 4000 | 96000.0 | — | Conversion of Exercise of derivative security at price 24.00 per share. | MOOS WALTER H | Director | — | 2026-02-20 00:00:00 | D |
| 1 | 4000 | 145440.0 | — | Sale at price 36.36 per share. | MOOS WALTER H | Director | — | 2026-02-20 00:00:00 | D |
| 2 | 53915 | — | — | Stock Award(Grant) at price 0.00 per share. | RODRIGUEZ RAUL R | Chief Executive Officer | — | 2026-02-17 00:00:00 | D |
| 3 | 20636 | — | — | Stock Award(Grant) at price 0.00 per share. | SCHORNO DEAN L | Chief Financial Officer | — | 2026-02-17 00:00:00 | D |
| 4 | 19497 | — | — | Stock Award(Grant) at price 0.00 per share. | FUREY RAYMOND J | General Counsel | — | 2026-02-17 00:00:00 | D |
| 5 | 19430 | — | — | Stock Award(Grant) at price 0.00 per share. | SANTOS DAVID A | Officer | — | 2026-02-17 00:00:00 | D |
| 6 | 18894 | — | — | Stock Award(Grant) at price 0.00 per share. | ROJKJAER LISA | Officer | — | 2026-02-17 00:00:00 | D |
| 7 | 80000 | 2192000.0 | — | Conversion of Exercise of derivative security at price 27.40 per share. | RODRIGUEZ RAUL R | Chief Executive Officer | — | 2026-01-26 00:00:00 | D |
| 8 | 6500 | 139786.0 | — | Conversion of Exercise of derivative security at price 18.70 - 24.20 per share. | SCHORNO DEAN L | Chief Financial Officer | — | 2025-12-22 00:00:00 | D |
| 9 | 2500 | — | — | Stock Award(Grant) at price 0.00 per share. | MOOS WALTER H | Director | — | 2025-05-23 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | -1.32K | -126.76K |
| TaxRateForCalcs | 0.05 | 0.00 | 0.00 | 0.04 |
| NormalizedEBITDA | 28.51M | -16.98M | -52.55M | -7.77M |
| TotalUnusualItems | 0.00 | 0.00 | -1.32M | -3.52M |
| TotalUnusualItemsExcludingGoodwill | 0.00 | 0.00 | -1.32M | -3.52M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 17.48M | -25.09M | -58.57M | -17.91M |
| ReconciledDepreciation | 2.23M | 1.24M | 998.00K | 1.16M |
| ReconciledCostOfRevenue | 18.65M | 7.11M | 1.75M | 1.08M |
| EBITDA | 28.51M | -16.98M | -53.87M | -11.29M |
| EBIT | 26.28M | -18.22M | -54.87M | -12.45M |
| NetInterestIncome | -5.83M | -4.60M | -3.02M | -4.81M |
| InterestExpense | 7.92M | 6.87M | 3.71M | 4.86M |
| InterestIncome | 2.09M | 2.27M | 684.00K | 47.00K |
| NormalizedIncome | 17.48M | -25.09M | -57.25M | -14.52M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 17.48M | -25.09M | -58.57M | -17.91M |
| TotalExpenses | 155.09M | 137.37M | 174.47M | 158.21M |
| TotalOperatingIncomeAsReported | 24.19M | -20.49M | -55.55M | -12.50M |
| DilutedAverageShares | 17.69M | 17.40M | 17.24M | 17.05M |
| BasicAverageShares | 17.58M | 17.40M | 17.24M | 17.05M |
| DilutedEPS | 0.99 | -1.44 | -3.40 | -1.10 |
| BasicEPS | 0.99 | -1.44 | -3.40 | -1.10 |
| DilutedNIAvailtoComStockholders | 17.48M | -25.09M | -58.57M | -17.91M |
| NetIncomeCommonStockholders | 17.48M | -25.09M | -58.57M | -17.91M |
| NetIncome | 17.48M | -25.09M | -58.57M | -17.91M |
| NetIncomeIncludingNoncontrollingInterests | 17.48M | -25.09M | -58.57M | -17.91M |
| NetIncomeContinuousOperations | 17.48M | -25.09M | -58.57M | -17.91M |
| TaxProvision | 881.00K | 0.00 | 0.00 | 605.00K |
| PretaxIncome | 18.37M | -25.09M | -58.57M | -17.31M |
| OtherIncomeExpense | -1.32M | -3.52M | ||
| SpecialIncomeCharges | 0.00 | 0.00 | -1.32M | -3.52M |
| RestructuringAndMergernAcquisition | 0.00 | 0.00 | 1.32M | 3.52M |
| NetNonOperatingInterestIncomeExpense | -5.83M | -4.60M | -3.02M | -4.81M |
| InterestExpenseNonOperating | 7.92M | 6.87M | 3.71M | 4.86M |
| InterestIncomeNonOperating | 2.09M | 2.27M | 684.00K | 47.00K |
| OperatingIncome | 24.19M | -20.49M | -54.23M | -8.97M |
| OperatingExpense | 136.44M | 130.26M | 172.72M | 157.13M |
| ResearchAndDevelopment | 23.38M | 24.52M | 60.27M | 65.24M |
| SellingGeneralAndAdministration | 113.06M | 105.74M | 112.45M | 91.89M |
| GrossProfit | 160.63M | 109.77M | 118.49M | 148.15M |
| CostOfRevenue | 18.65M | 7.11M | 1.75M | 1.08M |
| TotalRevenue | 179.28M | 116.88M | 120.24M | 149.24M |
| OperatingRevenue | 244.30M | 159.65M | 152.05M | 167.41M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 17.71M | 17.48M | 17.34M | 17.16M |
| ShareIssued | 17.71M | 17.48M | 17.34M | 17.16M |
| NetDebt | 2.93M | 26.82M | 14.99M | 1.02M |
| TotalDebt | 59.97M | 60.58M | 41.55M | 30.57M |
| TangibleBookValue | -23.81M | -42.52M | -28.57M | 30.37M |
| InvestedCapital | 62.97M | 30.96M | 25.83M | 50.29M |
| WorkingCapital | 71.80M | 46.00M | 50.69M | 90.91M |
| NetTangibleAssets | -23.81M | -42.52M | -28.57M | 30.37M |
| CapitalLeaseObligations | 285.00K | 977.00K | 2.10M | 10.65M |
| CommonStockEquity | 3.29M | -28.64M | -13.62M | 30.37M |
| TotalCapitalization | 55.70M | 23.73M | 25.83M | 50.29M |
| TotalEquityGrossMinorityInterest | 3.29M | -28.64M | -13.62M | 30.37M |
| StockholdersEquity | 3.29M | -28.64M | -13.62M | 30.37M |
| GainsLossesNotAffectingRetainedEarnings | 10.00K | 8.00K | -153.00K | -102.00K |
| OtherEquityAdjustments | 10.00K | 8.00K | -153.00K | -102.00K |
| RetainedEarnings | -1.39B | -1.41B | -1.38B | -1.32B |
| AdditionalPaidInCapital | 1.39B | 1.38B | 1.37B | 1.35B |
| CapitalStock | 18.00K | 17.00K | 174.00K | 172.00K |
| CommonStock | 18.00K | 17.00K | 174.00K | 172.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 160.69M | 145.87M | 147.90M | 136.95M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 97.39M | 92.60M | 82.68M | 73.40M |
| OtherNonCurrentLiabilities | 44.98M | 39.94M | 42.26M | 52.73M |
| LongTermDebtAndCapitalLeaseObligation | 52.41M | 52.66M | 40.42M | 20.67M |
| LongTermCapitalLeaseObligation | 0.00 | 285.00K | 972.00K | 759.00K |
| LongTermDebt | 52.41M | 52.37M | 39.45M | 19.91M |
| CurrentLiabilities | 63.30M | 53.27M | 65.21M | 63.55M |
| OtherCurrentLiabilities | 3.64M | 5.00M | 13.51M | |
| CurrentDeferredLiabilities | 27.80M | 17.04M | 13.51M | 10.51M |
| CurrentDeferredRevenue | 27.80M | 17.04M | 13.51M | 10.51M |
| CurrentDebtAndCapitalLeaseObligation | 7.56M | 7.92M | 1.13M | 9.89M |
| CurrentCapitalLeaseObligation | 285.00K | 692.00K | 1.13M | 9.89M |
| CurrentDebt | 7.27M | 7.23M | ||
| OtherCurrentBorrowings | 7.27M | 7.23M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 10.14M | 8.68M | 8.87M | 10.69M |
| PayablesAndAccruedExpenses | 17.81M | 15.99M | 36.70M | 18.95M |
| CurrentAccruedExpenses | 14.47M | 8.85M | 14.19M | 15.16M |
| Payables | 3.34M | 7.14M | 22.51M | 3.79M |
| AccountsPayable | 3.34M | 7.14M | 22.51M | 3.79M |
| TotalAssets | 163.98M | 117.22M | 134.28M | 167.33M |
| TotalNonCurrentAssets | 28.87M | 17.96M | 18.38M | 12.86M |
| OtherNonCurrentAssets | 1.44M | 3.06M | 640.00K | 974.00K |
| GoodwillAndOtherIntangibleAssets | 27.10M | 13.88M | 14.95M | 0.00 |
| NetPPE | 338.00K | 1.03M | 2.79M | 11.89M |
| AccumulatedDepreciation | -261.00K | -1.70M | -10.81M | -14.55M |
| GrossPPE | 599.00K | 2.73M | 13.59M | 26.44M |
| Leases | 0.00 | 2.11M | ||
| ConstructionInProgress | 74.00K | 691.00K | ||
| OtherProperties | 446.00K | 2.37M | 9.44M | 21.86M |
| MachineryFurnitureEquipment | 153.00K | 363.00K | 2.05M | 3.89M |
| Properties | 0.00 | 0.00 | ||
| CurrentAssets | 135.10M | 99.27M | 115.90M | 154.47M |
| OtherCurrentAssets | 10.16M | 6.26M | 8.26M | 7.41M |
| PrepaidAssets | 7.41M | |||
| Inventory | 6.00M | 5.52M | 9.12M | 6.62M |
| FinishedGoods | 1.90M | 1.31M | ||
| WorkInProcess | 2.66M | 162.00K | ||
| RawMaterials | 4.55M | 5.14M | ||
| Receivables | 41.62M | 30.55M | 40.32M | 15.47M |
| AccountsReceivable | 41.62M | 30.55M | 40.32M | 15.47M |
| AllowanceForDoubtfulAccountsReceivable | -246.00K | -180.00K | ||
| GrossAccountsReceivable | 41.86M | 30.73M | ||
| CashCashEquivalentsAndShortTermInvestments | 77.32M | 56.93M | 58.21M | 124.97M |
| OtherShortTermInvestments | 20.57M | 24.15M | 33.75M | 106.08M |
| CashAndCashEquivalents | 56.75M | 32.79M | 24.46M | 18.89M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 31.07M | -20.74M | -74.21M | 5.25M |
| RepurchaseOfCapitalStock | -10.00M | 0.00 | 0.00 | |
| IssuanceOfDebt | 0.00 | 19.95M | 19.54M | 0.00 |
| CapitalExpenditure | -396.00K | -15.00M | -450.00K | -627.00K |
| InterestPaidSupplementalData | 7.04M | 5.85M | 2.50M | 1.50M |
| IncomeTaxPaidSupplementalData | 331.00K | 0.00 | 0.00 | |
| EndCashPosition | 56.75M | 32.79M | 24.46M | 18.89M |
| BeginningCashPosition | 32.79M | 24.46M | 18.89M | 30.37M |
| ChangesInCash | 23.96M | 8.33M | 5.57M | -11.48M |
| FinancingCashFlow | -11.64M | 18.37M | 6.55M | 62.67M |
| CashFlowFromContinuingFinancingActivities | -11.64M | 18.37M | 6.55M | 62.67M |
| NetOtherFinancingCharges | -3.60M | -2.63M | -15.12M | 57.90M |
| ProceedsFromStockOptionExercised | 1.96M | 1.05M | 2.12M | 4.78M |
| NetCommonStockIssuance | -10.00M | 0.00 | 0.00 | |
| CommonStockPayments | -10.00M | 0.00 | 0.00 | |
| NetIssuancePaymentsOfDebt | 0.00 | 19.95M | 19.54M | 0.00 |
| NetLongTermDebtIssuance | 0.00 | 19.95M | 19.54M | 0.00 |
| LongTermDebtIssuance | 0.00 | 19.95M | 19.54M | 0.00 |
| InvestingCashFlow | 4.13M | -4.30M | 72.78M | -80.04M |
| CashFlowFromContinuingInvestingActivities | 4.13M | -4.30M | 72.78M | -80.04M |
| NetInvestmentPurchaseAndSale | 4.43M | 10.44M | 72.33M | -79.41M |
| SaleOfInvestment | 39.70M | 41.65M | 101.23M | 62.05M |
| PurchaseOfInvestment | -35.27M | -31.21M | -28.89M | -141.46M |
| NetIntangiblesPurchaseAndSale | -360.00K | -15.00M | 0.00 | |
| PurchaseOfIntangibles | -360.00K | -15.00M | 0.00 | |
| NetPPEPurchaseAndSale | 98.00K | 259.00K | 893.00K | -627.00K |
| SaleOfPPE | 98.00K | 259.00K | 893.00K | 0.00 |
| PurchaseOfPPE | 0.00 | -450.00K | -627.00K | |
| CapitalExpenditureReported | -36.00K | 0.00 | -450.00K | -627.00K |
| OperatingCashFlow | 31.47M | -5.74M | -73.76M | 5.88M |
| CashFlowFromContinuingOperatingActivities | 31.47M | -5.74M | -73.76M | 5.88M |
| ChangeInWorkingCapital | 153.00K | 9.52M | -29.05M | 9.72M |
| ChangeInOtherWorkingCapital | 12.22M | 3.33M | 1.18M | 2.53M |
| ChangeInOtherCurrentLiabilities | -692.00K | -2.17M | -13.08M | -8.62M |
| ChangeInOtherCurrentAssets | 615.00K | 1.07M | 7.77M | 8.04M |
| ChangeInPayablesAndAccruedExpense | 1.75M | -5.71M | 2.82M | 5.51M |
| ChangeInAccruedExpense | 5.55M | -5.35M | -967.00K | 5.47M |
| ChangeInPayable | -3.80M | -366.00K | 3.79M | 41.00K |
| ChangeInAccountPayable | -3.80M | -366.00K | 3.79M | 41.00K |
| ChangeInPrepaidAssets | -3.44M | 2.05M | -513.00K | 6.63M |
| ChangeInInventory | 764.00K | 1.17M | -2.38M | -4.88M |
| ChangeInReceivables | -11.06M | 9.77M | -24.85M | 501.00K |
| ChangesInAccountReceivables | -11.06M | 9.77M | -24.85M | 501.00K |
| OtherNonCashItems | 682.00K | 3.14M | ||
| StockBasedCompensation | 12.39M | 8.81M | 12.38M | 9.49M |
| AmortizationOfSecurities | -709.00K | -479.00K | -63.00K | 287.00K |
| DepreciationAmortizationDepletion | 2.23M | 1.24M | 998.00K | 1.16M |
| DepreciationAndAmortization | 2.23M | 1.24M | 998.00K | 1.16M |
| OperatingGainsLosses | -79.00K | 266.00K | -138.00K | |
| GainLossOnSaleOfPPE | -79.00K | 266.00K | -138.00K | 0.00 |
| NetIncomeFromContinuingOperations | 17.48M | -25.09M | -58.57M | -17.91M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for RIGL
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|